Clinical trials: Chimera
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers
To evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, including Factor XI activity and antigen levels, activated partial thromboplastin time, prothrombin time and international normalized ratio of…
- Trial name
- NCT03582462
- Testing
- IONIS FXI-LRx
- Where
- Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
COVID-19
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase 1b, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013 in healthy adults primed with a two-dose inactivated vaccine 6-9 months…
- Trial name
- NCT05396573
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Japanese Encephalitis
Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children
This study has aim to describe the immune response to the second dose of Japanese encephalitis chimeric vaccine (JECV) in children previously vaccinated with one dose of JECV 5 years ago.
- Trial name
- NCT01954810
- Testing
- Japanese encephalitis chimeric vaccine (JECV)
- Where
- Thailand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Khon Kaen University
Influenza
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
This is a Phase 1, randomized, controlled, dose-ranging clinical trial to assess the safety and immunogenicity of novel influenza A Group 1 and influenza A Group 2 mRNA chimeric hemagglutinin (HA) vaccine candidates given as…
- Trial name
- NCT07703514
- Testing
- cH15/3, cH4/3, cH5/1N1
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diffuse Large B Cell Lymphoma
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R/R). However, only 65% of patients achieve a complete metabolic response after this treatment.
- Trial name
- CARTROG (NCT06352242)
- Testing
- Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients, Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers
- Where
- 2 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified…
- Trial name
- NCT05108805
- Testing
- Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Tick-Borne Encephalitis
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death.
- Trial name
- NCT00118924
- Testing
- LGT(TP21)/DEN4
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers (HV)
A First-in-Human Study of ZE66-0205 in Healthy Volunteers
This first-in-human study will evaluate ZE66-0205 in healthy adults. The main purpose is to assess the safety and tolerability of single oral doses and, if evaluated, two doses given on Day 1.
- Trial name
- NCT07735728
- Testing
- ZE66-0205
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eilean Therapeutics
COVID-19
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase Ⅰa, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013.
- Trial name
- NCT05394012
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
COVID - 19
Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG
SpiN-Tec MCTI UFMG will be used as a vaccine booster against COVID-19 and will be evaluated using the active comparator, a vaccine approved by ANVISA (Brazilian Health Regulatory Agency).
- Trial name
- SpiN-Tec-001 (NCT07134725)
- Testing
- SpiN-Tec MCTI UFMG, Active Comparator: Covishield® vaccine, Active Comparator: Comirnaty® vaccine
- Where
- Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
HIV-1
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS).
- Trial name
- NCT06252402
- Testing
- CMV/HIV-CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Japanese Encephalitis
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.
- Trial name
- NCT01900444
- Testing
- IMOJEV
- Where
- 8 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
The purpose of this study is to compare the safety, tolerability and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] when administered intradermally in varied dosing schedules and via…
- Trial name
- NCT01765426
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Takeda
Japanese Encephalitis
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with…
- Trial name
- NCT02492165
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- Where
- Vietnam
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Leukemia
Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies
Immunotherapy is a promising therapeutic approach for patients with cancers. Patients with acute lymphoblastic leukemia (ALL) experiencing early relapse less than 18 months from diagnosis had very poor prognosis with 5-year…
- Trial name
- NCT03624686
- Testing
- peripheral blood
- Where
- Taiwan
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Influenza
Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients
Influenza infection in solid organ transplant recipients is associated with increased morbidity and mortality compared to non-transplanted controls, due in part to the effects of immunosuppression which is necessary to prevent…
- Trial name
- NCT02623075
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Encephalitis, Japanese Encephalitis
Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) .
- Trial name
- NCT01001988
- Testing
- Blood sample, JE-CV administered in Study JEC02
- Where
- 4 sites in Philippines, Thailand
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rheumatoid Arthritis, Juvenile
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Juvenile Rheumatoid Arthritis (JRA).
- Trial name
- NCT00036374
- Testing
- Infliximab
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Staphylococcus Aureus
First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133
In this clinical trial we will test a new approach for decolonization of S. aureus. As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five…
- Trial name
- HY-133 (NCT06290557)
- Testing
- HY_133
- Where
- 2 sites in Germany
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen